Ajanta Pharma is currently trading at Rs. 1982.00, up by 19.10 points or 0.97% from its previous closing of Rs. 1962.90 on the BSE.
The scrip opened at Rs. 1982.35 and has touched a high and low of Rs. 1994.90 and Rs. 1977.15 respectively. So far 5155 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 04-Oct-2016 and a 52 week low of Rs. 1103.00 on 18-Jan-2016.
Last one week high and low of the scrip stood at Rs. 2127.00 and Rs. 1951.00 respectively. The current market cap of the company is Rs. 17461.51 crore.
The promoters holding in the company stood at 73.78%, while institutions and non-institutions held 12.06% and 14.16% respectively.
Drug maker Ajanta Pharma’s new formulations facility set up at Guwahati with a capex of over Rs 300 crore is likely to be commercialised before March 2017. This will enable the company to build its strength in manufacturing and get more tax efficient. The facility will produce tablets, capsules, creams/ointments and sterile ophthalmic liquids.
Moreover, the company’s Dahej manufacturing facility, mainly dedicated for developed markets, will be operational in next financial year.
Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. The company is engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: